Genicular artery embolisation as a minimally invasive intervention to manage patients with mild-moderate osteoarthritis of the knee – setting up a new innovative service for Welsh patients.

Aneurin Bevan University Health Board0 个研究点目标入组 31 人开始时间: 2023年5月18日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1. Moderate to severe knee pain (VAS > 50 mm), and
•2. Pain refractory to at least 3 months of conservative therapies (anti-inflammatory drugs, physical therapy, muscle strengthening, or intra-articular injections), and
•3. Mild-moderate osteoarthritis of the knee as determined by Trauma and Orthopaedic procedure (previous Kellgren-Lawrence grade 1, 2 or 3 on a radiograph of the knee)
•4. Ages > 40 years old

•1. Current local infection
•2. Life expectancy less than 6 months
•3. Known advanced atherosclerosis, which is known lower extremity vascular or lower extremity symptoms thought to be secondary to arterial vascular disease (eg claudication, ischemic rest pain)
•4. Rheumatoid or infectious arthritis
•5. Prior knee surgery
•6. Uncorrectable coagulopathy including INR > 2.5 or platelets < 30,000
•7. Iodine allergy resulting in anaphylaxis
•8. Renal dysfunction as defined by GFR (eGFR) of <45 obtained within the past 60 days
•9. Contraindications for MR Imaging (such as claustrophobia, metallic fragment or foreign bones, implants or prosthesis)
•10. IV contrast allergy characterized by anaphylaxis or anaphylactoid reactions.
•11. Unable to provide written informed consent
•12. Unable to understand written English Language (required to complete validated PROMs)

发起方